Work

Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

Year: 2021

Type: erratum

Source: Leukemia

DOI: 10.1038/s41375-021-01245-x

Authors: Patrick A. Brown, John A. Kairalla, Joanne M. Hilden, ZoAnn E. Dreyer, Andrew J. Carroll, Nyla A. Heerema, Cindy Wang, Meenakshi Devidas, Lia Gore, Wanda L. Salzer, Naomi J. Winick, William L. Carroll, Elizabeth A. Raetz, Michael J. Borowitz, Donald Small, Mignon L. Loh, Stephen P. Hunger

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Florida Health, University of Florida, Children's Hospital Colorado, Texas Children's Hospital, University of Alabama at Birmingham, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, St. Jude Children's Research Hospital, United States Army Medical Research and Development Command, The University of Texas Southwestern Medical Center, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of California, San Francisco, UCSF Benioff Children's Hospital, UCSF Helen Diller Family Comprehensive Cancer Center, Children's Hospital of Philadelphia, University of Pennsylvania

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3168937796

Cites:

Cited by:

Related to: 10